ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

By A. Tsao. 2012

981 citations recorded by the source corpus.

Subfields: Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/e883fcd2f1ad9ca07519bb31e9047c437299aa94

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Peter W. Laird
2. S. Baylin
3. Eric S. Lander
4. Manel Esteller
5. Elaine R. Mardis
6. Jill P. Mesirov
7. Helga Thorvaldsdóttir
8. J. Herman

In Pulmonary and Respiratory Medicine

1. William Pao
2. Gregory Riely
3. P. Jänne
4. B. Hughes
5. B. Chan
6. J. Baselga
7. Marc Ladanyi
8. J. Chmielecki

Citations in the corpus

• Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing (2012, background): “Given their reported 2%–7% frequency in lung adenocarcinoma (Bergethon et al., 2012; Takeuchi et al., 2012), our study of 24 tumor/normal pairs may not be large enough to detect these rearrangements.”
• MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. (2016, neutral): “5 (59-84) 61 (30-93) 65 (42-93) Sex Male 9 (32) 30 (30) 62 (37) Female 19 (68) 69 (70) 107 (63) Smoking history, pack-years* Never-smoker 10 (36) 57 (58) 6 (4) # 10 3 (11) 10 (10) 11 (7) .”
• Comprehensive molecular profiling of lung adenocarcinoma (2014, background): “These mutations transform NIH3T3 cells and activate MAPK and PI(3)K signalling(32), supporting a driver role for mutant RIT1 in 2% of lung adenocarcinomas.”
• Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. (2015, background): “ROS1 rearrangements were first seen in 2007 with around 1-2% of NSCLC harbouring different ROS1 fusion variants (139,140).”
• OncoKB: A Precision Oncology Knowledge Base (2017, background): “For example, while explicit FDA approval of crizotinib in ROS1-rearranged NSCLC did not occur until March 2016, off-label use of crizotinib in ROS1 fusion-positive patients had been considered standard-of-care by several expert groups for some time 70–72 .”
• Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology (2018, methodology): “Similarly, some studies have suggested associations between the presence of ALK or ROS1 alterations and younger patient age.(30,35,181,215,216) Although other studies have indicated that these findings may reflect testing bias,(217) the documentation of an association between younger patient age and”
• Mechanisms of receptor tyrosine kinase activation in cancer (2018, positive): “Likewise, oncogenic tyrosine kinase fusions involving ROS1 have been identified in ~ 1% of NSCLCs [112], as well as in IMTs, cholangiocarcinoma, and GBM [94, 113].”